消息
MICLF's order intake has seen a significant increase of 119%, reaching 2.9 billion SEK, with strong contributions from all divisions, particularly Global Technologies and High Volume. The gross margin improved to 57% with EBIT close to 700 million SEK, representing a 29% margin. Order backlog increased to 5.25 billion SEK, providing a solid foundat...
22/07/2026 | Mycronic AB
Demire Deutsche Mittelstand Real Estate (DMRE.F) agreed to lease 10,000 square meters of its Reuterstraße 65 property in Bonn, Germany, to the Institute for Federal Real Estate. The institute will occupy the former Bonn Post headquarters starting in the autumn, the German real estate company said Tuesday.
22/07/2026 | DEMIRE Deutsche Mittelstand Real Estate AG
Public-sector tenants account for around 25% of DEMIRE's annual rental income, providing a stable source of revenue and contributing significantly to the quality of the company's tenant portfolio. DEMIRE's real estate portfolio comprises 42 properties with a lettable area of approximately 512,000 m², valued at around EUR 0.9 billion as of March 202...
22/07/2026 | DEMIRE Deutsche Mittelstand Real Estate AG
DEMIRE Deutsche Mittelstand Real Estate AG has secured a significant lease agreement with the Institute for Federal Real Estate (BImA) for approximately 10,000 m² of space in its property at Reuterstraße 65 in Bonn. This deal marks a key milestone in DEMIRE's efforts to establish the location as an international UN hub and underscores the attractiv...
22/07/2026 | DEMIRE Deutsche Mittelstand Real Estate AG
The European Medicines Agency (EMA) has accepted Almirall's submission of the extension of the Marketing Authorisation Application (MAA) for Ebglyss (lebrikizumab) in children and adolescents with moderate‑to‑severe atopic dermatitis. The application is supported by data from the paediatric clinical programme, including interim results from the piv...
22/07/2026 | Almirall, S.A.
Atopic dermatitis is a prevalent condition that often begins early in life, affecting approximately 60% of cases within the first year of life. Effective disease control is increasingly recognized as crucial to reduce long‑term disease burden and support healthier life trajectories for children living with atopic dermatitis. Almirall's commitment t...
22/07/2026 | Almirall, S.A.
Market sentiment reflects the uncertainty: a Zacks Rank of #5 (Strong Sell) contrasts with a Growth Score of A and a VGM Score of B; the Value Score of D signals near‑term execution risks. Following the Q3 forecast, Calix shares fell 15 % in pre‑market trading, though Northland Securities downgraded the company to “Outperform” from “Market Perform”...
22/07/2026 | Calix, Inc.
In the legal arena, a class action lawsuit was filed against Calix alleging violations of federal securities laws for false or misleading statements about margins, business, operations, and prospects from January 28 2026 to April 21 2026. Investors who purchased or acquired CALX securities in that window may join the lawsuit; the lead‑plaintiff app...
22/07/2026 | Calix, Inc.
Strategically, the company is embedding AI‑native capabilities across its Calix One platform, including Agent Workforce Cloud, intelligent automation, and cloud‑based applications, to automate marketing, customer support, and network operations. More than 1,200 customers deployed the platform; Agent Workforce Cloud sign‑ups tripled, and the migrati...
22/07/2026 | Calix, Inc.
Remaining performance obligations increased 11 % year‑over‑year to $386.4 million, driven by 14 new service‑provider customers and broader adoption of recurring offerings. For Q3 2026, Calix projected revenue of $301–$307 million—approximately 4 % sequential growth—and adjusted EPS of $0.37–$0.45, aligning with earlier guidance of 15 %–20 % revenue...
22/07/2026 | Calix, Inc.